Cancer remains among the leading causes of death worldwide. This scenario urges the translation of scientific research into clinical benefits to the patients.
New and highly effective therapies persist a challenge to be addressed. Our purpose is to improve the outcome of cancer patients by personalizing the drug delivery system.
18 million cases in 2018. 1 in 6 results in death
63 cancer drugs launching within the past five years
The global market for oncology therapeutic medicines will reach as much as $200 billion by 2022
Global oncology therapeutic medicines will average 10-13% growth over the next 5 years
A synthetic targeted drug delivery
Our synthetic molecules has the potential to be more scalable, efficient and with greater specificity than those of other therapeutic classes such as cell therapy, monoclonal antibodies and small molecules, because synthetic molecules present the same level of specificity, and beside are way too simple, their production is about 20 times cheaper than the monoclonal antibodies, for example.
We have developed an microfluidic platform designed to select synthetic molecules capable of a range of targeted medical interventions including chemical, radiation and immunological cancer therapies. The process development and technology of our platform convert selected synthetic molecules into clinical product candidates.
Making science available
We develop a new class of therapies with the potential to transform the cancer treatment through precision medicine. Key elements of our strategy are to collaborate with universities, private companies and hospitals to accelerate the delivery of our technology to the patients.
Industrialize synthetic molecules to advance and scale our platform;
Strengthen and expand our intellectual property to protect our platform;
Work in collaboration with universities and private companies to accelerate the development technology.
Or follow us on social platform
© 2019 Bioptamers